Zymeworks

Zymeworks stock climbed to a new 52-week high of $30.75 after a year-to-date gain of 115.42% and a market capitalization of about $2.13 billion. Analysts maintain a largely positive consensus with price targets between $31 and $60; several firms raised targets or ratings. Zymeworks also received FDA approval for therapies with Ziihera for HER2-positive gastric and gastroesophageal adenocarcinoma, and a definitive acquisition agreement for Theravance Biopharma at $17 per share was announced, including a contingent value right for ampreloxetine. » Altro su de.investing.com

The U.S. approval of the cancer drug Ziihera triggers a contractual one-time payment of $0.25 billion to Zymeworks. H.C. Wainwright raised the price target from $51 to $55 and reaffirmed the buy recommendation. Zymeworks' business model combines in-house research with strategic partners and benefits from oncology growth trends. » Altro su finanzen.net

Zymeworks shares climbed in premarket trading as the FDA decision on the PDUFA date of August 25, 2026, for zanidatamab (Ziihera) for HER2-positive gastric and gastroesophageal adenocarcinoma is awaited. Approval would immediately trigger a U.S. milestone payment of $250 million and could enable further global payments of up to $190 million. Analysts backed their assessments and raised price targets ahead of the date, and the planned acquisition of Theravance Biopharma is expected to strengthen the portfolio and cash flows with YUPELRI. The share price rise comes despite a weak overall market and a difficult biotech environment; the stock is trading at its highest level in more than a year. » Altro su de.investing.com